Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - Enzalutamide
- Status
- COMPLETED
- Phase
- NA
Clinical Trials Related to Enzalutamide
Related studies linked through entity extraction aliases.
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC
- Status
- UNKNOWN
- Phase
- PHASE2
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis
- Status
- COMPLETED
- Phase
- PHASE2
Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
- Status
- TERMINATED
- Phase
- PHASE1
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Status
- COMPLETED
- Phase
- N/A
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
- Status
- TERMINATED
- Phase
- NA
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
- Status
- COMPLETED
- Phase
- PHASE4
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
- Status
- TERMINATED
- Phase
- PHASE4
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
- Status
- TERMINATED
- Phase
- PHASE3